Does the progesterone receptor genetic polymorphism +331G/A hPR influence the risk of venous thromboembolism among postmenopausal women using hormone therapy? The ESTHER Study.
Hormone therapy (HT) increases venous thromboembolism (VTE) risk among postmenopausal women. Data on the influence of steroids receptors polymorphisms on this association remain scarce. Since progesterone receptor (hPR) is expressed in human veins and specific progestogens increase VTE risk, we investigated the impact of the functional +331G/A hPR polymorphism on the association of VTE with HT. Using the data of the ESTHER study, we showed that ORs for VTE in current users of progesterone or progestins were not significantly different by hPR+331G/A genotype status. hPR polymorphism appears not to have a significant effect on VTE risk related to HT.
Laboratoire de Génétique moléculaire, Pharmacogénétique et Hormonologie, Hôpital Bicêtre, AP-HP, Univ Paris-Sud, 78, rue du Général Leclerc, F-94275 Le Kremlin Bicêtre Cedex, France.
Elodie
E
Bouaziz
Marianne
M
Canonico
Céline
C
Verstuyft
Laure
L
Carcaillon
Frédéric
F
Martin
Pierre-Yves
PY
Scarabin
Anne
A
Guiochon-Mantel
D000368:Aged; D016022:Case-Control Studies; D015914:Estrogen Replacement Therapy / Q000009:adverse effects*; D004967:Estrogens / Q000009:adverse effects; D005260:Female; D006801:Humans; D008875:Middle Aged; D016017:Odds Ratio; D011110:Polymorphism, Genetic; D017698:Postmenopause; D011374:Progesterone / Q000009:adverse effects*; D011372:Progestins / Q000009:adverse effects*; D011980:Receptors, Progesterone / Q000235:genetics*; D012307:Risk Factors; D054556:Venous Thromboembolism / Q000209:etiology*
D004967:Estrogens; D011372:Progestins; D011980:Receptors, Progesterone; D011374:Progesterone